NOTE

🌱 created from: asco

asco_2024

1. NATALEE: Subgroup Analysis of Adjuvant Ribociclib + NSAI vs NSAI Alone in Patients With Stage II/III Node-Negative HR+/HER2- EBC
2. postMONARCH: Abemaciclib + Fulvestrant vs Fulvestrant Monotherapy for HR+/HER2- Advanced BC After Progression on CDK4/6 Inhibitor + ET
3. SACI-IO HR+: Phase II Trial of Sacituzumab Govitecan ± Pembrolizumab in HR+/HER3- Metastatic Breast Cancer
4. DESTINY-Breast07: Trastuzumab Deruxtecan ± Pertuzumab for Previously Untreated HER2+ Metastatic Breast Cancer
5. DESTINY-Breast06: Phase III Trial of Trastuzumab Deruxtecan vs Chemotherapy in Previously Treated HR+/HER2-Low or Ultralow MBC
6. I-SPY 2.2: Neoadjuvant Datopotamab Deruxtecan Plus Durvalumab in High-Risk Stage II-III HER2-Negative Breast Cancer
7. A-BRAVE: Phase III Trial of Adjuvant Avelumab vs Observation in Patients With Early TNBC With Residual Disease Post Neoadjuvant CT or at High Risk After Surgery and Adjuvant CT
8. ASCO to Clinic: Breast Cancer
9. ASCO 2024 Breast Cancer WC
10. ASCO 2024 Breast Cancer: Key Studies in Breast Cancer
11. ASC4FIRST: Phase III Trial of Asciminib vs Investigator-Selected TKIs in Newly Diagnosed CML
12. DREAMM-8: Phase III Trial of Belantamab Mafodotin + Pomalidomide/Dexamethasone (BPd) vs Pomalidomide + Bortezomib/Dexamethasone (PVd) in RRMM
13. Integrated Palliative Care in AML/MDS
14. MANIFEST-2 Update: Phase III Trial of Pelabresib Plus Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis
15. Pirtobrutinib Prior to CAR T Therapy
16. DEB: Tucidinostat + R-CHOP in DLBCL
17. ECHELON-3: Phase III, Placebo-Controlled Trial of Brentuximab Vedotin in Combination With Lenalidomide and Rituximab in R/R DLBCL
18. FELIX: Phase Ib/II Study of Obecabtagene Autoleucel in Adults With Relapsed/Refractory B-Cell ALL
19. Cytopenias and MNs After CAR T Therapy
20. IMROZ: Phase III Study of Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone vs Bortezomib, Lenalidomide, and Dexamethasone for Transplant-Ineligible, Newly Diagnosed MM
21. BENEFIT/IFM 2020-05: Phase III Trial of Isa-VRd vs Isa-Rd in Patients With Transplant-Ineligible NDMM
22. PERSEUS MRD Analysis
23. ASCO 2024: Leukemias
24. Lymphomas
25. Multiple Myeloma
26. ASCO 2024 Heme Malig WC
27. ASCO 2024: Hematologic Malignancies
28. EVOKE-01: Phase III Trial of Sacituzumab Govitecan vs Docetaxel in Patients With Previously Treated Advanced NSCLC
29. CROWN: 5-Yr Update of First-line Lorlatinib vs Crizotinib in Advanced ALK-Positive NSCLC
30. KRYSTAL-12: Phase III Trial of Adagrasib vs Docetaxel in Previously Treated Advanced KRASG12C-Mutated NSCLC
31. LAURA: Phase III Trial of Osimertinib vs Placebo After Definitive Chemoradiotherapy in Unresectable Stage III EGFR-Mutated NSCLC
32. ADRIATIC: Phase III Trial of Consolidation Therapy With Durvalumab for Limited-Stage Small-Cell Lung Cancer
33. PALOMA-3 SC Amivantamab
34. DESTINY-Lung02: Final Analysis of Trastuzumab Deruxtecan in Previously Treated HER2-Mutated Metastatic NSCLC
35. Beamion LUNG-1
36. WU-KONG1: Phase II Study of Sunvozertinib in Advanced NSCLC and EGFR Exon 20 Insertion Mutations
37. REACH PC: Telehealth vs In-Person Visits for Palliative Care in NSCLC
38. ASCO to Clinic: Lung Cancers
39. ASCO 2024 Lung Cancer WC
40. ASCO 2024: Lung Cancer
41. ASCO to Clinic: Skin Cancer
42. Genitourinary Cancers
43. ASCO 2024 GU Cancers WC
44. Genitourinary Cancers: Conference to Clinic
45. ASCO 2024 GU Cancers WC
46. RUBY Post Hoc Analysis: Survival Outcomes With Dostarlimab Plus Chemotherapy by Type of MMR Deficiency in Patients With Endometrial Cancer
47. PACS: Sintilimab Plus Paclitaxel and Cisplatin as Neoadjuvant Treatment for FIGO Stage IB3 and IIA2 Cervical Cancer
48. Immunotherapy Advances in Gynecologic Cancers: Insights From ASCO 2024